Glofitamab Achieves Central Nervous System Disease Control in Relapsed B-ALL: A Case Report in a Transplant-Ineligible Jehovah's Witness Patient (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-805; "Rituximab (8 cycles) was added to blinatumomab, and IT chemotherapy was intensified. Off-label zanubrutinib did not elicit a response...Off-label glofitamab with obinutuzumab pretreatment was initiated alongside additional radiation... To our knowledge, this is the first reported case of glofitamab achieving CNS disease control in B-ALL, extending prior observations from B-cell lymphomas in which glofitamab penetrates the CSF. The CD20-negative systemic relapse with maintained CNS control, in the setting of biopsy-confirmed CD20-positive CNS disease, supports compartment-specific selective pressure and biologic plausibility of CD20-directed bispecific activity in CNS sanctuary disease. Glofitamab may represent a therapeutic option for CNS-involved B-ALL in transplantineligible patients, including those declining blood products."
Case report • Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CD19 • CD20
|
|
Basak Basbayraktar MD 1; Volha Chapiolkina MD 1; Natalie Rafaeli MD 1; Sara Taveras Alam MD 1; Ulas Akyuz MD 2
|